Imaging β-amyloid plaques and neurofibrillary tangles in the aging human brain

Current Pharmaceutical Design

Volumn 10, Issue 13, 2004, Pages 1469-1492

  Mathis, C A ^a,b   Wang, Y ^a   Klunk, W E ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b PRESBYTERIAN UNIVERSITY HOSPITAL   (United States)

Author keywords

Alzheimer's disease; Amyloid ; Imaging; Neurofibrillary tangles; PET; SPECT

Indexed keywords

ACRIDINE ORANGE; AMYLOID BETA PROTEIN; BASIC FIBROBLAST GROWTH FACTOR; BENZOTHIAZOLE DERIVATIVE; CARBON 11; CARBON 14; CHRYSAMINE G; CONGO RED; FLUORINE 18; GADOLINIUM PENTETATE; INDIUM 111; IODINE 123; IODINE 124; IODINE 125; IRON; MONOCLONAL ANTIBODY; PEPTIDE DERIVATIVE; PROTEIN DERIVATIVE; PUTRESCINE; RADIOLIGAND; RADIOPHARMACEUTICAL AGENT; SERUM AMYLOID P; STILBENE DERIVATIVE; STREPTAVIDIN; TECHNETIUM 99M; THIOFLAVINE; TRACER; TRANSFERRIN RECEPTOR; UNCLASSIFIED DRUG; UNINDEXED DRUG; X 34;

ALZHEIMER DISEASE; BINDING AFFINITY; BINDING SITE; BLOOD BRAIN BARRIER; DEGENERATIVE DISEASE; DRUG DESIGN; DRUG HALF LIFE; DRUG PENETRATION; DRUG TARGETING; DRUG UPTAKE; HUMAN; IMAGING SYSTEM; IN VITRO STUDY; IN VIVO STUDY; ISOTOPE LABELING; LIGAND BINDING; LIPOPHILICITY; MOLECULAR SIZE; NEUROFIBRILLARY TANGLE; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; REVIEW; SENILE PLAQUE; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

AGING; AMYLOID BETA-PROTEIN; ANIMALS; BRAIN; DIAGNOSTIC IMAGING; HUMANS; NEUROFIBRILLARY TANGLES; SENILE PLAQUES;

EID: 2342446265     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/1381612043384772     Document Type: Review

References (123)

1. Katzman R. Education and the prevalence of dementia and Alzheimer's disease. Neurology 1993; 43: 13-20.
2. Price DL, Sisodia SS. Mutant genes in familial Alzheimer's disease and transgenic models. Annu Rev Neurosci 1998; 21: 479-505.
3. Khachaturian ZS. An overview of Alzheimer's disease research. Am J Med 1998; 104: 26S-31S; discussion 39S-42S.
4. Terry RD. Where in the brain does Alzheimer's disease begin? Ann Neurol 2000; 47: 421.
5. Alzheimer A. Allgemeine Zeitschrift der Psychiatric 1907; 64: 146-148.
6. Glenner GG, Wong CW. Alzheimer's disease and Down's syndrome: sharing of a unique cerebrovascular amyloid fibril protein. Biochem Biophys Res Commun 1984; 122: 1131-5.
7. Hilbich C, Kisters-Woike B, Reed J, Masters CL, Beyreuther K. Aggregation and secondary structure of synthetic amyloid beta A4 peptides of Alzheimer's disease J Mol Biol 1991; 218: 149-63.
8. Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 2002; 297: 353-6.
9. Patrick GN, Zukerberg L, Nikolic M, de la Monte S, Dikkes P, Tsai LH. Conversion of p35 to p25 deregulates Cdk5 activity and promotes neurodegeneration. Nature 1999; 402: 615-22.
10. Hyman BT. Down syndrome and Alzheimer disease. Prog Clin Biol Res 1992; 379: 123-42.
11. Hyman BT, West HL, Rebeck GW, Lai F, Mann DM. Neuropathological changes in Down's syndrome hippocampal formation. Effect of age and apolipoprotein E genotype. Arch Neurol 1995; 52: 373-8.
12. Braak H, Braak E, Bohl J, Reintjes R. Age, neurofibrillary changes, A beta-amyloid and the onset of Alzheimer's disease Neurosci Lett 1996; 210: 87-90.
13. Goldman WP, Price JL, Storandt M, Grant EA, McKeel DW, Rubin EH, Morris JC. Absence of cognitive impairment or decline in preclinical Alzheimer's disease. Neurology 2001; 56: 361-7.
14. Selkoe DJ. Alzheimer's disease: genes, proteins, and therapy. Physiol Rev 2001; 81: 741-66.
15. Mann DM, Jones D, South PW, Snowden JS, Neary D. Deposition of amyloid beta protein in non-Alzheimer dementias: evidence for a neuronal origin of parenchymal deposits of beta protein in neurodegenerative disease. Acta Neuropathol 1992; 83: 415-9.
16. Naslund J, Haroutunian V, Mohs R, Davis KL, Davies P, Greengard P, Buxbaum JD. Correlation between elevated levels of amyloid beta-peptide in the brain and cognitive decline JAMA 2000; 283: 1571-7.
17. Selkoe DJ. Physiological production of the beta-amyloid protein and the mechanism of Alzheimer's disease. Trends Neurosci 1993; 16: 403-9.
18. Yankner BA, Caceres A, Duffy LK. Nerve growth factor potentiates the neurotoxicity of beta amyloid. Proc Natl Acad Sci U S A 1990; 87: 9020-3.
19. Mattson MP, Cheng B, Davis D, Bryant K, Lieberburg I, Rydel RE. beta-Amyloid peptides destabilize calcium homeostasis and render human cortical neurons vulnerable to excitotoxicity. J Neurosci 1992; 12: 376-89.
20. Mattson MP, Tomaselli KJ, Rydel RE. Calcium-destabilizing and neurodegenerative effects of aggregated beta-amyloid peptide are attenuated by basic FGF. Brain Res 1993; 621: 35-49.
21. Shearman MS, Ragan CI, Iversen LL. Inhibition of PC12 cell redox activity is a specific, early indicator of the mechanism of beta-amyloid-mediated cell death. Proc Natl Acad Sci USA 1994; 91: 1470-4.
22. Pike CJ, Burdick D, Walencewicz AJ, Glabe CG, Cotman CW. Neurodegeneration induced by beta-amyloid peptides in vitro: the role of peptide assembly state. J Neurosci 1993; 13: 1676-87.
23. Simmons LK, May PC, Tomaselli KJ, Rydel RE, Fuson KS, Brigham EF, et al. Secondary structure of amyloid beta peptide correlates with neurotoxic activity in vitro. Mol Pharmacol 1994; 45: 373-9.
24. Lambert MP, Barlow AK, Chromy BA, Edwards C, Freed R, Liosatos M, et al. Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins. Proc Natl Acad Sci USA 1998; 95: 6448-53.
25. Goate A, Chartier-Harlin MC, Mullan M, Brown J, Crawford F, Fidani L, et al. Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease. Nature 1991; 349: 704-6.
26. Selkoe DJ, Podlisny MB. Deciphering the genetic basis of Alzheimer's disease. Annu Rev Genomics Hum Genet 2002; 3: 67-99.
27. Younkin SG. The AAP and PS1/2 mutations linked to early onset familial Alzheimer's disease increase the extracellular concentration and A beta 1-42 (43). Rinsho Shinkeigaku 1997; 37: 1099.
28. Goedert M, Crowther RA, Spillantini MG. Tau mutations cause frontotemporal dementias. Neuron 1998; 21: 955-8.
29. Consensus Panel Report. Neurobiol Aging 1997; 18(4S): S1-S2.
30. Selkoe DJ, Bell DS, Podlisny MB, Price DL, Cork LC. Conservation of brain amyloid proteins in aged mammals and humans with Alzheimer's disease. Science 1987; 235: 873-7.
31. Morris JC, Rubin EH. Clinical diagnosis and course of Alzheimer's disease. Psychiatr Clin North Am 1991; 14: 223-36.
32. Price JL. Diagnostic criteria for Alzheimer's disease. Neurobiol Aging 1997: 18: S67-S70.
33. Haroutunian V, Perl DP, Purohit DP, Marin D, Khan K, Lantz M, et al. Regional distribution of neuritic plaques in the nondemented elderly and subjects with very mild Alzheimer disease. Arch Neurol 1998; 55: 1185-91.
34. Kaplan B, Haroutunian V, Koudinov A, Patael Y, Pras M, Gallo G. Biochemical assay for amyloid beta deposits to distinguish Alzheimer's disease from other dementias. Clin Chim Acta 1999; 280: 147-59.
35. Klunk WE. Biological markers of Alzheimer's disease. Neurobiol Aging 1998; 19: 145-7.
36. Hardy JA, Higgins GA. Alzheimer's disease: the amyloid cascade hypothesis. Science 1992; 256: 184-5.
37. Dovey HF, John V, Anderson JP, Chen LZ, de Saint Andrieu P, Fang LY, et al. Functional gamma-secretase inhibitors reduce beta-amyloid peptide levels in brain. J Neurochem 2001; 76: 173-81.
38. Olson RE, Copeland RA, Seiffert D. Progress towards testing the amyloid hypothesis: inhibitors of APP processing. Curr Opin Drug Discov Devel 2001; 4: 390-401.
39. Schenk D, Barbour R, Dunn W, Gordon G, Grajeda H, Guido T, et al. Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 1999; 400: 173-7.
40. Check E. Nerve inflammation halts trial for Alzheimer's drug. Nature 2002; 415: 462.
41. Nicoll JA, Wilkinson D, Holmes C, Steart P, Markham H, Weller RO. Neuropathology of human Alzheimer disease after immunization with amyloid-beta peptide: a case report. Nat Med 2003; 9: 448-52.
42. Greenberg SM, Bacskai BJ, Hyman BT. Alzheimer disease's double-edged vaccine. Nat Med 2003; 9: 389-90.
43. Hock C, Konietzko U, Streffer JR, Tracy J, Signorell A, Muller-Tillmanns B, et al. Antibodies against beta-amyloid slow cognitive decline in Alzheimer's disease. Neuron 2003: 38: 547-54.
44. Winblad B, Blum KI. Hints of a therapeutic vaccine for Alzheimer's? Neuron 2003; 38: 517-8.
45. Persuy P, Defossez A, Delacourte A, Tramu G, Bouchez B, Arnott G. Anti-PHF antibodies: an immunohistochemical marker of the lesions of the Alzheimer's disease. Characterization and comparison with Bodian's silver impregnation. Virchows Arch A Pathol Anat Histopathol 1985; 407: 13-23.
46. Vechterova L, Kontsekova E, Zilka N, Ferencik M, Ravid R, Novak M. DC11: a novel monoclonal antibody revealing Alzheimer's disease-specific tau epitope. Neuroreport 2003; 14: 87-91.
47. Small GW, Agdeppa ED, Kepe V, Satyamurthy N, Huang SC, Barrio JR. In vivo brain imaging of tangle burden in humans. J Mol Neurosci 2002; 19: 323-7.
48. Fillit HM, Refolo L. Tau and Alzheimer's disease: the long road to anti-tangle therapeutics. J Mol Neuroscience 2002; 19: 249-50.
49. Meegalla SK, Plossl K, Kung MP, Chumpradit S, Stevenson DA, Kushner SA, et al. Synthesis and characterization of technetium-99m-labeled tropanes as dopamine transporter-imaging agents. J Med Chem 1997; 40: 9-17.
50. Lemaire C, Cantineau R, Guillaume M, Plenevaux A, Christiaens L. Fluorine-18-altanserin: a radioligand for the study of serotonin receptors with PET: radiolabeling and in vivo biologic behavior in rats. J Nucl Med 1991; 32: 2266-72.
51. Scheffel U, Pogun S, Stathis M, Boja JW, Kuhar MJ. In vivo labeling of cocaine binding sites on dopamine transporters with [3H]WIN 35,428. J Pharmacol Exp Ther 1991; 257: 954-8.
52. Hume SP, Myers R, Bloomfield PM, Opacka-Juffry J, Cremer JE, Ahier RG, et al. Quantitation of carbon-11-labeled raclopride in rat striatum using positron emission tomography. Synapse 1992; 12: 47-54.
53. 11C](+)McN5652 as a radiotracer for imaging serotonin uptake sites with PET. Life Sci 1993; 53: 883-92.
54. 11C]WAY 100635: a radioligand for imaging 5-HT1A receptors with positron emission tomography. Life Sci 1994; 55: PL403-7.
55. Frost J. J. Pharmacokinetic aspects of the in vivo non-invasive study of neuroreceptors in man. Boca Raton FL: CRC Press 1982.
56. Eckelman WC. The use of in vitro models to predict the distribution of receptor binding radiotracers in vivo. Int J Rad Appl Instrum B 1989; 16: 233-45.
57. Feher M, Sourial E, Schmidt JM. A simple model for the prediction of blood-brain partitioning. Int J Pharm 2000; 201: 239-47.
58. Dishino DD, Welch MJ, Kilbourn MR, Raichle ME. Relationship between lipophilicity and brain extraction of C-11-labeled radiopharmaceuticals. J Nucl Med 1983; 24:1030-8.
59. Salminen T, Pulli A, Taskinen J. Relationship between immobilised artificial membrane chromatographic retention and the brain penetration of structurally diverse drugs. J Pharm Biomed Anal 1997; 15: 469-77.
60. Levin VA. Relationship of octanol/water partition coefficient and molecular weight to rat brain capillary permeability. J Med Chem 1980; 23: 682-4.
61. Doze P, Van Waarde A, Elsinga PH, Hendrikse NH, Vaalburg W. Enhanced cerebral uptake of beta-adrenergic ligands by modulation of P-glycoprotein function in the blood-brain barrier. Synapse 2000; 36: 66-74.
62. Maggio JE, Stimson ER, Ghilardi JR, Allen CJ, Dahl CE, Whitcomb DC, et al. Reversible in vitro growth of Alzheimer disease beta-amyloid plaques by deposition of labeled amyloid peptide. Proc Natl Acad Sci USA 1992; 89: 5462-6.
63. Saito Y, Buciak J, Yang J, Pardridge WM. Vector-mediated delivery of 125I-labeled beta-amyloid peptide A beta 1-40 through the blood-brain barrier and binding to Alzheimer disease amyloid of the A beta 1-40/vector complex. Proc Natl Acad Sci USA 1995; 92: 10227-31.
64. Mackic JB, Bading J, Ghiso J, Walker L, Wisniewski T, Frangione B, et al. Circulating amyloid-beta peptide crosses the blood-brain barrier in aged monkeys and contributes to Alzheimer's disease lesions. Vascul Pharmacol 2002; 38: 303-13.
65. Ghilardi JR, Catton M, Stimson ER, Rogers S, Walker LC, Maggio JE, et al. Intra-arterial infusion of [125I]A beta 1-40 labels amyloid deposits in the aged primate brain in vivo. Neuroreport 1996; 7: 2607-11.
66. Lee HJ, Zhang Y, Zhu C, Duff K, Pardridge WM. Imaging brain amyloid of Alzheimer disease in vivo in transgenic mice with an Abeta peptide radiopharmaceutical. J Cereb Blood Flow Metab 2002; 22: 223-31.
67. Wengenack TM, Curran GL, Poduslo JF. Targeting alzheimer amyloid plaques in vivo. Nat Biotechnol 2000; 18: 868-72.
68. Poduslo JF, Wengenack TM, Curran GL, Wisniewski T, Sigurdsson EM, Macura SI, et al. Molecular targeting of Alzheimer's amyloid plaques for contrast-enhanced magnetic resonance imaging. Neurobiol Dis 2002; 11: 315-29.
69. Wadghiri YZ, Sigurdsson EM, Sadowski M, Elliott JI, Li Y, Scholtzova H, et al. Detection of Alzheimer's amyloid in transgenic mice using magnetic resonance microimaging. Magn Reson Med 2003; 50: 293-302.
70. Bornebroek M, Verzijlbergen JF, Haan J, Van Scheyen EJ, Verhoeff NP, Pauwels EK, et al. Potential for imaging cerebral amyloid deposits using 123I-labelled serum amyloid P component and SPET. Nucl Med Commun 1996; 17: 929-33.
71. Friedland RP, Shi J, Lamanna JC, Smith MA, Perry G. Prospects for noninvasive imaging of brain amyloid beta in Alzheimer's disease. Ann N Y Acad Sci 2000; 903: 123-8.
72. Shi J, Perry G, Smith M. A, Friedland RP. Vascular abnormalities: the insidious pathogenesis of Alzheimer's disease. Neurobiol Aging 2000; 21: 357-61.
73. Majocha RE, Reno JM, Friedland RP, VanHaight C, Lyle LR, Marotta CA. Development of a monoclonal antibody specific for beta/A4 amyloid in Alzheimer's disease brain for application to in vivo imaging of amyloid angiopathy. J Nucl Med 1992; 33: 2184-9.
74. Friedland RP, Majocha RE, Reno JM, Lyle LR, Marotta CA. Development of an anti-A beta monoclonal antibody for in vivo imaging of amyloid angiopathy in Alzheimer's disease. Mol Neurobiol 1994; 9: 107-13.
75. Friedland RP, Kalaria R, Berridge M, Miraldi F, Hedera P, Reno J, et al. Neuroimaging of vessel amyloid in Alzheimer's disease. Ann N Y Acad Sci 1997; 826: 242-7.
76. Bickel U, Lee VM, Trojanowski JQ, Pardridge WM. Development and in vitro characterization of a cationized monoclonal antibody against beta A4 protein: a potential probe for Alzheimer's disease. Bioconjug Chem 1994; 5: 119-25.
77. Stokes MI, Trickey RJ. Screening for neurofibrillary tangles and argyrophilic plaques with Congo Red and polarized light. J Clin Pathol 1973; 26: 241-2.
78. Klunk WE, Pettegrew JW, Abraham DJ. Quantitative evaluation of congo red binding to amyloid-like proteins with a beta-pleated sheet conformation. J Histochem Cytochem 1989; 37: 1273-81.
79. Khachaturian ZS. Diagnosis of Alzheimer's disease. Arch Neurol 1985; 42: 1097-105.
80. Tubis M, Blahd WH, Nordyke RA. The preparation and use of radioiodinated Congo red in detecting amyloidosis. J.Am.Pharmaceut.Assoc. 1960; 49: 422-425.
81. Klunk WE, Debnath ML, Pettegrew JW. Development of small molecule probes for the beta-amyloid protein of Alzheimer's disease. Neurobiol Aging 1994; 15: 691-8.
82. Klunk WE, Debnath ML, Pettegrew JW. Chrysamine-G binding to Alzheimer and control brain: autopsy study of a new amyloid probe. Neurobiol Aging 1995; 16: 541-8.
83. Mathis CA, Mahmood K, Debnah ML, Klunk WE. Synthesis of a lipophilic, radioiodinated ligand with high affinity to amyloid protein in Alzheimer's disease brain tissue. J. Labelled Compounds and Radiopharmaceuticals 1997; 40: 94-95.
84. Mathis CA, Bishop JE, Gerdes JM, Whitney JM, Brennan KM, Jagust WJ. Synthesis and evaluation of high affinity, aryl-substituted [18F]fluoropropylbenzamides for dopamine D-2 receptor studies. Int J Rad Appl Instrum B 1992; 19: 571-88.
85. Han H, Cho CG, Lansbury PT. Journal of the American Chemical Society 1996; 118: 4506-4507.
86. Zhen W, Han H, Anguiano M, Lemere CA, Cho CG, Lansbury PT. Synthesis and amyloid binding properties of rhenium complexes: preliminary progress toward a reagent for SPECT imaging of Alzheimer's disease brain J Med Chem 1999; 42: 2805-15.
87. 99mTc-MAMA-chrysamine G, a probe for beta-amyloid protein of Alzheimer's disease. Eur J Nucl Med 1999; 26: 1392-9.
88. Lynn RK, Donielson DW, Ilias AM, Kennish JM, Wong K, Matthews HB. Metabolism of bisazobiphenyl dyes derived from benzidine, 3,3′-dimethylbenzidine or 3,3′-dimethoxybenzidine to carcinogenic aromatic amines in the dog and rat. Toxicol Appl Pharmacol 1980; 56: 248-58.
89. Klunk WE, Bacskai BJ, Mathis CA, Kajdasz ST, McLellan ME, Frosch MP, et al. Imaging Abeta plaques in living transgenic mice with multiphoton microscopy and methoxy-X04, a systemically administered Congo red derivative. J Neuropathol Exp Neurol 2002; 61: 797-805.
90. Styren SD, Hamilton RL, Styren GC, Klunk WE. X-34, a fluorescent derivative of Congo red: a novel histochemical stain for Alzheimer's disease pathology. J Histochem Cytochem 2000; 48: 1223-32.
91. Hsiao K, Chapman P, Nilsen S, Eckman C, Harigaya Y, Younkin S, et al. Correlative memory deficits, Abeta elevation, and amyloid plaques in transgenic mice. Science 1996; 274: 99-102.
92. Skovronsky DM, Zhang B, Kung MP, Kung HF, Trojanowski JQ, Lee VM. In vivo detection of amyloid plaques in a mouse model of Alzheimer's disease. Proc Natl Acad Sci USA 2000; 97: 7609-14.
93. Zhuang ZP, Kung MP, Hou C, Skovronsky DM, Gur TL, Plossl K, et al. Radioiodinated styrylbenzenes and thioflavins as probes for amyloid aggregates. J Med Chem 2001; 44: 1905-14.
94. Klunk WE, Bacskai BJ, Mathis CA, Kajdasz ST, McLellan ME, Frosch MP, et al. Imaging Abeta plaques in living transgenic mice with multiphoton microscopy and methoxy-X04, a systemically administered Congo red derivative. J Neuropathol Exp Neurol 2002; 61: 797-805.
95. 11C-labeling of (E,E)-1-(3′,4′-dihydroxystyryl)-4-(3′-methoxy-4′ -hydroxystyryl)benzene for PET imaging of amyloid deposits. J. Labelled Compounds and Radiopharmaceuticals 2002; 45: 647-664.
96. Shoji M, Kawarabayashi T, Sato M, Sasaki A, Matsubara E, Iizuka T, et al. Systemic overexpression of a C-terminal fragment of human amyloid beta-protein precursor causes accumulation of Alzheimer beta-amyloid fibrils in pancreas of transgenic mice. Gerontology 1996; 42 Suppl 1: 48-56.
97. Christie G, Markwell RE, Gray CW, Smith L, Godfrey F, Mansfield F, et al. Alzheimer's disease: correlation of the suppression of beta-amyloid peptide secretion from cultured cells with inhibition of the chymotrypsin-like activity of the proteasome. J Neurochem 1999; 73: 195-204.
98. LeVine H. Quantification of beta-sheet amyloid fibril structures with thioflavin T. Methods Enzymol 1999; 309: 274-84.
99. Klunk WE, Wang YM, Hung GF, Debnah ML, Holt DP, Mathis CA. Uncharged thioflavin-T derivatives bind to amyloid-beta protein with high affinity and readily enter the brain. Life Sci 2001; 69: 1471-1484.
100. Klunk WE, Wang Y, Huang GF, Debnath ML, Holt DP, Shao L, et al. The binding of 2-(4′-methylaminophenyl)benzothiazole to postmortem brain homogenates is dominated by the amyloid component. J Neurosci 2003; 23: 2086-92.
101. 1A receptor. Psychopharmacology 2001; 157: 111-4.
102. Mathis CA, Bacskai BJ, Kajdasz ST, McLellan ME, Frosch MP, Hyman BT, et al. A lipophilic thioflavin-T derivative for positron emission tomography (PET) imaging of amyloid in brain. Bioorg Med Chem Lett 2002; 12: 295-8.
103. Bacskai BJ, Kajdasz ST, Christie RH, Carter C, Games D, Seubert P, et al. Imaging of amyloid-beta deposits in brains of living mice permits direct observation of clearance of plaques with immunotherapy. Nat Med 2001; 7: 369-72.
104. 11C-labeled 6-substituted 2-arylbenzothiazoles as amyloid imaging agents. J Med Chem 2003; 46: 2740-54.
105. Engler H, Nordberg A, Blomqvist G, Bergström M, Estrada S, Barletta J, et al. First human study with a benzothiazole amyloid-imaging agent in Alzheimer's disease and control subjects. Neurobiol Aging 2002; 23: S429.
106. Bergstrom M, Grahnen A, Langstrom B. Eur J. Clin Pharmacol 2003; 59: 357-66.
107. Wang Y, Klunk WE, Huang GF, Debnath ML, Holt DP, Mathis CA. Synthesis and evaluation of 2-(3′-iodo-4′-aminophenyl)-6-hydroxybenzothiazole for in vivo quantitation of amyloid deposits in Alzheimer's disease. J Mol Neurosci 2002; 19: 11-6.
108. Wang Y, Mathis C. A, Huang G.-F, Debnah M. L, Holt D, Shao L, Klunk W. E. J Mol Neurosci 2004; in press.
109. Zhuang ZP, Kung MP, Hou C, Plossl K, Skovronsky D, Gur TL, et al. IBOX(2-(4′-dimethylaminophenyl)-6-iodobenzoxazole): a ligand for imaging amyloid plaques in the brain. Nucl Med Biol 2001; 28: 887-94.
110. Ono M, Kung M. P, Hou C, Kung HF. Benzofuran derivatives as Abeta-aggregate-specific imaging agents for Alzheimer's disease. Nucl Med Biol 2002; 29: 633-42.
111. Kung MP, Hou C, Zhuang ZP, Zhang B, Skovronsky D, Trojanowski JQ, et al. IMPY: an improved thioflavin-T derivative for in vivo labeling of beta-amyloid plaques. Brain Res 2002; 956: 202-10.
112. Zhuang ZP, Kung MP, Wilson A, Lee CW, Plossl K, Hou C, et al. Structure-activity relationship of imidazo[1,2-a]pyridines as ligands for detecting beta-amyloid plaques in the brain. J Med Chem 2003; 46: 237-43.
113. Kung HF, Lee CW, Zhuang ZP, Kung MP, Hou C, Plossl K. Novel stilbenes as probes for amyloid plaques. J Am Chem Soc 2001; 123: 12740-1.
114. 11C-labeled stilbene derivatives as Abeta-aggregate-specific PET imaging agents for Alzheimer's disease. Nucl Med Biol 2003; 30: 565-71.
115. Shoghi-Jadid K, Small GW, Agdeppa ED, Kepe V, Ercoli LM, Siddarth P, et al. Localization of neurofibrillary tangles and beta-amyloid plaques in the brains of living patients with Alzheimer disease. Am J Geriatr Psychiatry 2002; 10: 24-35.
116. Klunk WE, Engler H, Nordberg A, Wang Y, Blomqvist G, Holt D, et al. Annuals Neurol 2004; in press.
117. Shimadzu H, Suemoto T, Suzuki M, Shiomitsu T, Okamura N, Kudo Y, et al. A novel probe for imaging of amyloid-beta: Synthesis of F-18-labelled BF108, an acridine orange analog. J Labelled Compounds and Radiopharmaceuticals 2003; 46: 765-772.
118. Kung MP, Skovronsky DM, Hou C, Zhuang ZP, Gur TL, Zhang B, et al. Detection of amyloid plaques by radioligands for Abeta40 and Abeta42: potential imaging agents in Alzheimer's patients. J Mol Neurosci 2003; 20: 15-24.
119. Lee CW, Kung MP, Hou C, Kung HF. Dimethylamino-fluorenes: ligands for detecting beta-amyloid plaques in the brain. Nucl Med Biol 2003; 30: 573-80.
120. Suemoto T, Okamura N, Shiomtsu T, Suzuki M, Shimadzu H, Akatsu H, et al. In vivo labeling of amyloid with BF-108. Neurosci Res 2004; 48: 65-74.
121. Bailey DL, Adamson KL. Nuclear medicine: from photons to physiology. Curr Pharm Design 2003; 9(11): 903-16.
122. Conway KA, Baxter EW, Felsenstein KM, Reitz AB. Emerging beta-amyloid therapies for the treatment of Alzheimer's disease. Curr Pharm Design 2003; 9(6): 427-47.
123. Schimmoller F, Higaki JN, Cordell B. Amyloid forming proteases: therapeutic targets for Alzheimer's disease. Curr Pharm Design 2002; 8(28): 2521-31.